4 Big Pharmaceutical Stocks to Buy for the Rest of 2015

in

While most people consider big pharmaceutical stocks very defensive, the fact of the matter is that they offer investors terrific growth and income possibilities, which can lead to outstanding total returns. In a new research report, SunTrust Robinson Humphrey analysts expect the industry to outperform in 2015, driven by a solid new product cycle, an attractive five-year growth rate and, plain and simple, stocks that are currently under-owned as a percentage of the S&P 500.